OA10946A - Substituted 3,5-diphenyl-1,2,4-triazoles and theiruse as pharmaceutical metal chelators - Google Patents

Substituted 3,5-diphenyl-1,2,4-triazoles and theiruse as pharmaceutical metal chelators Download PDF

Info

Publication number
OA10946A
OA10946A OA9800247A OA9800247A OA10946A OA 10946 A OA10946 A OA 10946A OA 9800247 A OA9800247 A OA 9800247A OA 9800247 A OA9800247 A OA 9800247A OA 10946 A OA10946 A OA 10946A
Authority
OA
OAPI
Prior art keywords
lower alkyl
bis
hydroxyphenyl
hydroxy
hydrogen
Prior art date
Application number
OA9800247A
Other languages
English (en)
Inventor
Rene Lattman
Pierre Acklin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10946(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of OA10946A publication Critical patent/OA10946A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA9800247A 1996-06-25 1998-12-24 Substituted 3,5-diphenyl-1,2,4-triazoles and theiruse as pharmaceutical metal chelators OA10946A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25

Publications (1)

Publication Number Publication Date
OA10946A true OA10946A (en) 2003-02-27

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800247A OA10946A (en) 1996-06-25 1998-12-24 Substituted 3,5-diphenyl-1,2,4-triazoles and theiruse as pharmaceutical metal chelators

Country Status (37)

Country Link
US (3) US6465504B1 (es)
EP (1) EP0914118B1 (es)
JP (1) JP3541042B2 (es)
KR (1) KR100616378B1 (es)
CN (1) CN1146415C (es)
AP (1) AP1127A (es)
AR (1) AR007479A1 (es)
AT (1) ATE226435T1 (es)
AU (1) AU718037B2 (es)
BG (1) BG64248B1 (es)
BR (1) BR9709973A (es)
CA (1) CA2255951C (es)
CY (2) CY2429B1 (es)
CZ (1) CZ291470B6 (es)
DE (3) DE122007000020I1 (es)
DK (1) DK0914118T3 (es)
ES (1) ES2187785T3 (es)
FR (1) FR06C0049I2 (es)
GE (1) GEP20084355B (es)
HK (1) HK1020530A1 (es)
HU (1) HU226232B1 (es)
IL (1) IL127212A0 (es)
LT (1) LTC0914118I2 (es)
LU (1) LU91291I2 (es)
MY (1) MY129541A (es)
NL (1) NL300248I2 (es)
NO (3) NO317180B1 (es)
NZ (1) NZ333308A (es)
OA (1) OA10946A (es)
PL (1) PL194758B1 (es)
PT (1) PT914118E (es)
RU (1) RU2208010C2 (es)
SI (1) SI0914118T1 (es)
SK (1) SK284319B6 (es)
TR (1) TR199802693T2 (es)
TW (1) TW533205B (es)
WO (1) WO1997049395A1 (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
CA2547196A1 (en) * 2003-12-19 2005-06-30 Novartis Ag Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
AU2006208638B2 (en) * 2005-01-28 2010-03-04 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
KR20070101314A (ko) * 2005-02-10 2007-10-16 노파르티스 아게 약물 처리과정을 개선하기 위한 방법
EA014772B1 (ru) * 2005-05-31 2011-02-28 Новартис Аг Лечение заболеваний печени, в патогенезе которых задействовано железо
AU2006303514B2 (en) * 2005-10-19 2010-06-24 Novartis Ag Dispersible tablets comprising deferasirox
PL1945272T3 (pl) * 2005-11-01 2014-03-31 Novartis Ag Sposób prowadzenia scyntygraffi
NZ572299A (en) * 2006-05-09 2010-07-30 Novartis Ag Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
MX2008014837A (es) 2006-05-23 2008-12-01 Novartis Ag Metodo para el tratamiento de hemocromatosis hereditaria.
CL2007002026A1 (es) * 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
CN101500561A (zh) * 2006-08-04 2009-08-05 诺瓦提斯公司 应用铁螯合剂治疗内分泌功能障碍
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
CA2670313C (en) * 2006-11-29 2013-02-12 Novartis Ag Polymorphic forms of deferasirox (icl670a)
EP2108013A2 (en) * 2007-01-29 2009-10-14 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Crystalline forms of deferasirox
CN101677970A (zh) * 2007-05-14 2010-03-24 诺瓦提斯公司 铁螯合剂用于治疗心肌梗塞的用途
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
WO2009147529A1 (en) * 2008-06-02 2009-12-10 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
NZ595271A (en) 2009-03-19 2013-08-30 Los Angeles Biomed Res Inst Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
AU2010329487A1 (en) 2009-12-07 2012-06-14 Mapi Pharma Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
CA2805568A1 (en) 2010-07-08 2012-01-12 Ratiopharm Gmbh Oral dosage form of deferasirox
WO2012025935A2 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
AP3578A (en) * 2010-10-01 2016-02-08 Cipla Ltd Pharmaceutical composition comprising deferasirox
US9018389B2 (en) 2010-11-24 2015-04-28 Alembic Pharmaceuticals, Ltd. Process for the preparation of Deferasirox
US9796605B2 (en) 2011-01-14 2017-10-24 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
EP2766049A1 (en) 2011-10-14 2014-08-20 Photocure ASA Photodynamic diagnosis of abnormalities of the epithelial lining of the oesophagus with the means of a 5-ala ester
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) * 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
AU2014224252B2 (en) * 2013-03-06 2016-09-22 Biocon Limited Process for the preparation of Deferasirox
MX361055B (es) * 2013-03-08 2018-11-26 Novartis Ag Formulaciones orales de deferasirox.
CN105377256A (zh) * 2013-05-10 2016-03-02 奇普拉股份有限公司 低剂量药物组合物
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20240110004A (ko) 2014-03-14 2024-07-12 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
EP2946771B1 (en) 2014-05-20 2019-03-20 Sanovel Ilac Sanayi ve Ticaret A.S. Water-dispersible tablet formulation comprising deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
EP3365339A1 (en) 2015-10-23 2018-08-29 Vifor (International) AG Novel ferroportin inhibitors
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
EP4052698A1 (en) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH84663A4 (es) 1963-01-24 1964-11-14
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
SI0914118T1 (en) 2003-04-30
CN1146415C (zh) 2004-04-21
NO2006017I1 (no) 2006-12-18
BR9709973A (pt) 1999-08-10
CY2007005I1 (el) 2010-07-28
PT914118E (pt) 2003-02-28
BG64248B1 (bg) 2004-07-30
PL194758B1 (pl) 2007-07-31
NL300248I2 (nl) 2007-03-01
DE69716602D1 (de) 2002-11-28
CA2255951A1 (en) 1997-12-31
LTPA2007001I1 (lt) 2018-06-25
CY2007005I2 (el) 2018-12-12
NO2006017I2 (no) 2011-07-04
NO2018014I1 (no) 2018-04-17
ATE226435T1 (de) 2002-11-15
JP2000507601A (ja) 2000-06-20
FR06C0049I1 (es) 2007-03-09
BG103003A (en) 1999-09-30
DE122007000020I2 (de) 2010-12-30
CY2429B1 (en) 2004-11-12
AU3262997A (en) 1998-01-14
HU226232B1 (en) 2008-07-28
CA2255951C (en) 2006-10-10
EP0914118B1 (en) 2002-10-23
KR100616378B1 (ko) 2006-08-28
PL330119A1 (en) 1999-04-26
TW533205B (en) 2003-05-21
AU718037B2 (en) 2000-04-06
WO1997049395A1 (en) 1997-12-31
CZ427298A3 (cs) 1999-03-17
US6465504B1 (en) 2002-10-15
DK0914118T3 (da) 2003-02-24
NO2018014I2 (no) 2018-11-19
NO986024D0 (no) 1998-12-21
CZ291470B6 (cs) 2003-03-12
FR06C0049I2 (fr) 2007-04-27
NO317180B1 (no) 2004-09-06
MY129541A (en) 2007-04-30
HUP9903111A3 (en) 2000-06-28
AR007479A1 (es) 1999-10-27
NL300248I1 (nl) 2007-02-01
AP1127A (en) 2002-12-06
GEP20084355B (es) 2008-04-29
HUP9903111A2 (hu) 2000-01-28
JP3541042B2 (ja) 2004-07-07
LU91291I9 (es) 2018-12-27
LTC0914118I2 (lt) 2018-12-27
CN1223579A (zh) 1999-07-21
US6596750B2 (en) 2003-07-22
DE122007000020I1 (de) 2007-05-24
EP0914118A1 (en) 1999-05-12
ES2187785T3 (es) 2003-06-16
HK1020530A1 (en) 2000-05-12
IL127212A0 (en) 1999-09-22
LU91291I2 (fr) 2007-01-29
US20030069273A1 (en) 2003-04-10
SK178598A3 (en) 1999-06-11
KR20050098029A (ko) 2005-10-10
SK284319B6 (sk) 2005-01-03
DE69716602T2 (de) 2003-06-26
NO986024L (no) 1998-12-21
NZ333308A (en) 2000-05-26
RU2208010C2 (ru) 2003-07-10
AP9801407A0 (en) 1998-12-31
US6723742B2 (en) 2004-04-20
TR199802693T2 (xx) 1999-05-21
US20030203954A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
OA10946A (en) Substituted 3,5-diphenyl-1,2,4-triazoles and theiruse as pharmaceutical metal chelators
US4683232A (en) Heterocyclic compounds having cardiotonic use
IE913571A1 (en) Pyridine and pyridine N-oxide derivatives of diarylmethyl- piperidines or piperazines, compositions and use thereof
CZ410397A3 (cs) Deriváty 4-fenylaminothiazolu, způsob jejich přípravy a farmaceutické přípravky, které je obsahují
DE69222280T2 (de) Kondensierte Benzeoxyessigsäurederivate
US4640917A (en) 2-phenyl-hexahydro-1,2,4-triazine-3,5-diones
WO1996034856A1 (en) 2-ureido-benzamide derivatives
JPH0653748B2 (ja) １Ｈ，３Ｈ−ピロロ〔１，２−ｃ〕チアゾ−ル誘導体、その製造法およびそれを含有する組成物
MXPA02006033A (es) Nuevos derivados amino substituidos ramificados de 3-amino-1-fenil-1h[1,2,4]triazol, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
DE69107137T2 (de) 1-(alkoxy-iminoalkyl)imidazolderivate.
KR850000452B1 (ko) 카바모일옥시아미노-1, 4-벤조디아제핀의 제조방법
US3813412A (en) Certain triazolyl benzhydrol compounds
KR100568044B1 (ko) 치환된3,5-디페닐-1,2,4-트리아졸및제약학상금속킬레이트화제로서그의용도
EP0457716A1 (de) Naphthalinderivate
JPH02286663A (ja) アゾール―１―アルカンアミドおよびそれらの製法
US4022788A (en) Indane tetrol amines
CZ284006B6 (cs) Chinolinové sloučeniny, způsob jejich přípravy a farmaceutické přípravky tyto sloučeniny obsahující
WO1988003531A1 (en) Cardiotonic imidazolylphenylpyrrol-2-ones